Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Letter to the Editor

Modifications to the HEALing Communities Study in response to COVID-19 related disruptions

The COVID-19 pandemic has coincided with a rise in opioid-related overdose deaths and placed significant burdens on medical, substance use and mental health treatment systems that might otherwise implement evidence-based practices (EBPs) to reduce these deaths (Centers for Disease Control and Prevention, 2020). These COVID-19 related disruptions significantly impacted the implementation of the Communities That HEAL (CTH) Intervention. As a consequence, the study leadership and federal sponsors agreed to modify the design of the HEALing Communities Study (HCS; The HEALing Communities Study Consortium, 2020) in January 2021. While the study design, hypotheses, measurements, and primary and secondary outcomes remain unchanged, the study end date will be extended by 12 months (ending 3/31/24) as follows:

- The implementation period for Wave 1 communities will be extended by 6 months (ending 6/30/22), and the implementation period for Wave 2 communities will be delayed by 6 months (7/1/22–6/30/23).
- The comparison period for testing the main and secondary hypotheses between Wave 1 and Wave 2 communities will be 7/1/21–6/30/22.
- The community engagement intervention (Sprague Martinez et al., 2020) remains unchanged except that the implementation phases (Phases 5 and 6) will be extended by 6 months in Wave 1 communities. Many of the advisory and coalition meetings have been converted to video format (e.g., Zoom).
- The menu of EBPs outlined in the ORCCA (Winhusen et al., 2020) remains unchanged except that the strategies will be delivered for an additional 6 months in Wave 1 communities. Coalitions have emphasized strategies that can be delivered through telehealth.
- The communication campaigns (Lefebvre et al., 2020) in Wave 1 communities will be reduced to 4 unique campaigns (i.e., stigma, naloxone, MOUD initiation, MOUD retention) with the option to re-run any of the previous four for a 5th campaign. We anticipate Wave 2 communities will select and tailor 2 campaigns.
- The implementation science (Knudsen et al., 2020) and health economics (Aldridge et al., 2020) components will remain largely unchanged.
- With the exception of aligning follow-up measures to correspond with new time periods, the approach to data collection and analysis for the main and secondary hypotheses (Slavova et al., 2020) remains unchanged.

These modifications will allow additional time and resources to mitigate the impact of the COVID-19 pandemic on the implementation of the CTH intervention. The extension also allows us to preserve the full 12-month intervention for Wave 2 communities, as per the original commitment. HCS remains committed to reducing opioid overdose deaths by 40% and creating a model for addressing the national opioid crisis.

Contributors

STW drafted the manuscript. All authors provided input and have approved the final letter.

Trial registration

Clinical Trials.gov http://www.clinicaltrials.gov; Identifier: NCT04111939.

Role of the funding source

This research was supported by the National Institutes of Health through the NIH HEAL Initiative under award numbers UM1DA049394, UM1DA049406, UM1DA049412, UM1DA049415, UM1DA049417. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or its NIH HEAL Initiative.

Declaration of competing interest

The authors report no declarations of interest.

References

Aldridge, A.P., Barbosa, C., Barocas, J.A., Bush, J.L., Chhatwal, J., Harlow, K.J., Hyder, A., Linas, B.P., McCollister, K.E., Morgan, J.R., Murphy, S.M., Savitzky, C., Schackman, B.R., Seiber, E.E., Starbird, L.E., Villani, J., Zarkin, G.A., 2020. Health economic design for cost, cost-effectiveness and simulation analyses in the HEALing Communities Study. Drug Alcohol Depend. 217, 108336 https://doi.org/10.1016/j.drugalcdep.2020.108336.

Centers for Disease Control and Prevention, 2020. Increase in Fatal Drug Overdoses Across the United States Driven by Synthetic Opioids Before and During the COVID-19 Pandemic. Publication Number CDCCHAN-00438. December Available at https://emergency.cdc.gov/han/2020/han00438.asp (Accessed February 14, 2021).

Knudsen, H.K., Drainoni, M.-L., Gilbert, L., Huerta, T.R., Oser, C.B., Aldrich, A.M., Campbell, A.N.C., Crable, E.L., Garner, B.R., Glasgow, L.M., Goddard-Eckrich, D., Marks, K.R., McAleney, A.S., Oga, E.A., Scala, A.L., Walker, D.M., 2020. Model and approach for assessing implementation context and fidelity in the HEALing Communities Study. Drug Alcohol Depend. 217, 108330 https://doi.org/10.1016/j.drugalcdep.2020.108330.

Lefebvre, R.C., Chandler, R.K., Helme, D.W., Kerner, R., Mann, S., Stein, M.D., Reynolds, J., Slater, M.D., Anakarayene, A.R., Beard, D., Burrea, O., Frkovic, J., Hedrick, H., Lewis, N., Rodgers, E., 2020. Health communication campaigns to drive demand for evidence-based practices and reduce stigma in the HEALing Communities Study. Drug Alcohol Depend. 217, 108338 https://doi.org/10.1016/j.drugalcdep.2020.108338.

Slavova, S., LaRochelle, M.R., Root, E., Feaster, D.J., Villani, J., Knott, C.E., Talbert, J., Mack, A., Crane, D., Bemson, D., Booth, A., Walsh, S.L., 2020. Operationalizing and

https://doi.org/10.1016/j.drugalcdep.2021.108669
Received 23 February 2021
Available online 13 March 2021
0376-8716/© 2021 Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Nabila El-Bassel\textsuperscript{d}
\textsuperscript{d} Columbia University, New York, NY, USA

Lashawn M. Glasgow\textsuperscript{e}
\textsuperscript{e} RTI International, Research Triangle Park, NC, USA

Rebecca D. Jackson\textsuperscript{f}
\textsuperscript{f} The Ohio State University, Columbus, OH, USA

Emmanuel A. Oga\textsuperscript{g}
\textsuperscript{g} RTI International, Research Triangle Park, NC, USA

Jeffrey H. Samet\textsuperscript{j}
\textsuperscript{j} Boston University, Boston, MA, USA

Sharon L. Walsh\textsuperscript{j}
\textsuperscript{j} University of Kentucky, Lexington, KY, USA

Gary A. Zarkin\textsuperscript{k}
\textsuperscript{k} RTI International, Research Triangle Park, NC, USA

\textsuperscript{a} Corresponding author at: Health Behavior and Health Systems, School of Public Health, The University of North Texas Health Science Center, 3500 Camp Bowie Blvd, Fort Worth, TX, 76107, USA.

E-mail address: scott.walters@unthsc.edu (S.T. Walters).